Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy

Citation
N. Morikawa et al., Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy, BIOL PHAR B, 23(6), 2000, pp. 784-787
Citations number
13
Categorie Soggetti
Pharmacology & Toxicology
Journal title
BIOLOGICAL & PHARMACEUTICAL BULLETIN
ISSN journal
09186158 → ACNP
Volume
23
Issue
6
Year of publication
2000
Pages
784 - 787
Database
ISI
SICI code
0918-6158(200006)23:6<784:POCAMN>2.0.ZU;2-4
Abstract
This report investigates the pharmacokinetics of cytosine arabinoside (Ara- C), methotrexate (MTX), nimustine (ACNU) and valproic acid (VPA) in cerebro spinal fluid (CSF) during CSF perfusion chemotherapy. Japanese woman with d isseminated glioblastoma was, on admission, on a stable oral regimen of pro longed-release VPA tablets (Depakene(TM)-R), 400 mg twice a day, for seizur e control. Twelve courses of CSF perfusion chemotherapy with Ara-C, MTX, an d ACNU were administered. Plasma samples and CSF samples via Ommaya reservo irs were obtained during the eleventh course of treatment. The Ara-C and AC RTU concentrations were measured by HPLC. The MTX and VPA concentrations we re measured by fluorescence polarization immunoassay. During CSF perfusion themotherapy, the highest CSF concentrations of Ara-C, MTX, and ACNU were observed at the end of the perfusion and decreased in a monoexponential pattern. The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71h, respectively. No anticancer drugs were detectable in plas ma during CSF perfusion chemotherapy. Before CSF perfusion chemotherapy; th e free VPA concentration in plasma was 14.4% of the total VPA concentration . The mean total and fi ee VPA concentrations in plasma were 78.0 +/- 0.8 a nd 10.9 +/- 0.3 mu g/ml, respectively. The free VPA concentrations in plasm a and in CSF were of similar values. At the end of perfusion, the lowest fr ee VPA concentration in CSF was 30.3% of that at the initiation of perfusio n. The free VPA concentrations in CSF at 3, 7, 23, and 47 h after the end o f perfusion were 79.8, 93.5, 100.9, and 100.9% respectively of that at the initiation of perfusion. During CSF perfusion chemotherapy, the ratio of fr ee VPA concentrations to the total VPA in CSF was 86.3 +/- 6.9%. The VPA co ncentrations in CSF rapidly decreased during the CSF perfusion but recovere d to pre-treatment levels within 7 h.